NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
Updated: Feb 21
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).
Sponsor
Arch Oncology
ClinicalTrials.gov Identifier: NCT04445701
Official Title: A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
First Posted : June 24, 2020
Click here to see details on ClinicalTrials.gov
Drug: AO-176 Drug: AO-176 + Dex
Drug: AO-176 + Dex + Bort
Anti-CD47 Monoclonal Antibody AO-176 (Code C159600)
Anti-CD47 Monoclonal Antibody AO-176
AO 176
AO-176
AO176
Locations
United States, Arizona
United States, Florida
United States, Georgia
United States, Massachusetts
United States, Minnesota
United States, Washington
United States, Wisconsin